Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John M. Goldman

Showing results (61-70 of 96) with videos related to

Pageof 10
Sort By:
Blood|December 31, 2002
Dendritic cells from CML patients have altered actin organization, reduced antigen processing, and impaired migrationRong Dong, Kate Cwynarski, Alan Entwistle, et al.
Blood|February 2, 2006
Serial measurement of BCR-ABL transcripts in the peripheral blood after allogeneic stem cell transplantation for chronic myeloid leukemia: an attempt to define patients who may not require further therapyJaspal Kaeda, Derville O'Shea, Richard M Szydlo, et al.
The New England Journal of Medicine|October 10, 2003
Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemiaTim P Hughes, Jaspal Kaeda, Susan Branford, et al.
Blood|October 17, 2008
Primitive quiescent CD34+ cells in chronic myeloid leukemia are targeted by in vitro expanded natural killer cells, which are functionally enhanced by bortezomibAgnes S M Yong, Keyvan Keyvanfar, Nancy Hensel, et al.
Haematologica|March 26, 2003
Chronic myeloid leukemia in chronic phase responding to imatinib: the occurrence of additional cytogenetic abnormalities predicts disease progressionSarah Marktel, David Marin, Nicola Foot, et al.
Blood|September 14, 2010
Efficacy of tyrosine kinase inhibitors (TKIs) as third-line therapy in patients with chronic myeloid leukemia in chronic phase who have failed 2 prior lines of TKI therapyAmr R Ibrahim, Christos Paliompeis, Marco Bua, et al.
Blood|November 6, 2007
In vivo kinetics of kinase domain mutations in CML patients treated with dasatinib after failing imatinibJamshid S Khorashad, Dragana Milojkovic, Puja Mehta, et al.
British Journal of Haematology|October 15, 2013
A common novel splice variant of SLC22A1 (OCT1) is associated with impaired responses to imatinib in patients with chronic myeloid leukaemiaJacob Grinfeld, Gareth Gerrard, Mary Alikian, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|July 5, 2011
EBMT risk score predicts outcome of allogeneic hematopoietic stem cell transplantation in patients who have failed a previous transplantation procedureKatayoun Rezvani, Edward J Kanfer, David Marin, et al.
Blood|August 22, 2008
European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poorDavid Marin, Dragana Milojkovic, Eduardo Olavarria, et al.
Pageof 10

Showing results (61-70 of 96) with videos related to

Sort By:
Pageof 10
Blood|December 31, 2002
Dendritic cells from CML patients have altered actin organization, reduced antigen processing, and impaired migrationRong Dong, Kate Cwynarski, Alan Entwistle, et al.
Blood|February 2, 2006
Serial measurement of BCR-ABL transcripts in the peripheral blood after allogeneic stem cell transplantation for chronic myeloid leukemia: an attempt to define patients who may not require further therapyJaspal Kaeda, Derville O'Shea, Richard M Szydlo, et al.
The New England Journal of Medicine|October 10, 2003
Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemiaTim P Hughes, Jaspal Kaeda, Susan Branford, et al.
Blood|October 17, 2008
Primitive quiescent CD34+ cells in chronic myeloid leukemia are targeted by in vitro expanded natural killer cells, which are functionally enhanced by bortezomibAgnes S M Yong, Keyvan Keyvanfar, Nancy Hensel, et al.
Haematologica|March 26, 2003
Chronic myeloid leukemia in chronic phase responding to imatinib: the occurrence of additional cytogenetic abnormalities predicts disease progressionSarah Marktel, David Marin, Nicola Foot, et al.
Blood|September 14, 2010
Efficacy of tyrosine kinase inhibitors (TKIs) as third-line therapy in patients with chronic myeloid leukemia in chronic phase who have failed 2 prior lines of TKI therapyAmr R Ibrahim, Christos Paliompeis, Marco Bua, et al.
Blood|November 6, 2007
In vivo kinetics of kinase domain mutations in CML patients treated with dasatinib after failing imatinibJamshid S Khorashad, Dragana Milojkovic, Puja Mehta, et al.
British Journal of Haematology|October 15, 2013
A common novel splice variant of SLC22A1 (OCT1) is associated with impaired responses to imatinib in patients with chronic myeloid leukaemiaJacob Grinfeld, Gareth Gerrard, Mary Alikian, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|July 5, 2011
EBMT risk score predicts outcome of allogeneic hematopoietic stem cell transplantation in patients who have failed a previous transplantation procedureKatayoun Rezvani, Edward J Kanfer, David Marin, et al.
Blood|August 22, 2008
European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poorDavid Marin, Dragana Milojkovic, Eduardo Olavarria, et al.
Pageof 10